Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 18/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4489947 | 0.89 | SLC6A4 (0.57) | SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4 | |
| Cadaverine Tartrate SCHEMBL4492714 | 0.88 | SLC6A4 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4 | |
| SCHEMBL5821369 | 0.88 | SLC6A4 (0.59) | SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4 | |
| SCHEMBL4491619 | 0.88 | SLC6A4 (0.59) | SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4 | |
| Cadaverine Tartrate SCHEMBL4486328 | 0.82 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4 | |
| Cadaverine Tartrate SCHEMBL4324711 | 0.81 | SLC6A4 (0.51) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C9 | |
| Cadaverine Tartrate SCHEMBL4495055 | 0.81 | SLC6A4 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4 | |
| Cadaverine Tartrate SCHEMBL4490576 | 0.81 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3CYP2D6NOS2 | |
| Cadaverine Tartrate SCHEMBL4486465 | 0.80 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3NOS2KCNH2 | |
| Cadaverine Tartrate SCHEMBL4483380 | 0.80 | SLC6A4 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619096-B2 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1638934-B1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | LILLY CO ELI (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | SLC6A2, SLC6A3, SLC18A2 | SLC6A2 1/4885SLC6A3 2/4885SLC6A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.